Idenix Pharmaceuticals (IDIX)

[DewDiligence]

>[TMC125] is a twice daily drug whereas IDIX feels the pk of their product can support once daily dosing (which in HIV we know means a lot)<

Once-daily dosing is mandatory for any drug that hopes to supersede Sustiva in a 3-drug cocktail such as Atripla. Now that SoC first-line HIV therapy has moved to once-daily dosing (e.g. Atripla, Truvada + Reyataz/ritonavir, Truvada + Kaletra), it is not going to move back to BID dosing.